Cargando…
First-line endocrine treatment of breast cancer: aromatase inhibitor or antioestrogen?
Until recently, endocrine therapy for breast cancer was relatively simple. If the tumour expressed hormone receptors, regardless of stage and age, tamoxifen was indicated. While this largely remains the case for premenopausal women, clinical trials in postmenopausal women have broadened our choice t...
| Autores principales: | , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2004
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395329/ https://www.ncbi.nlm.nih.gov/pubmed/14710200 http://dx.doi.org/10.1038/sj.bjc.6601508 |